flanders.bio

Will you be joining us at the Convention? As a proud partner of Flanders Investment & Trade (FIT), we'll be at the Flanders International Business Convention on November 5th & 6th and we'd love to see you there. ❗ Contact us to receive your exclusive flanders.bio member discount! Why you should attend: 👉 B2B speed-dating with experts from abroad 👉 Networking with the #lifesciences ecosystem 👉 Expert seminars and keynotes from leading speakers 👉 Valuable insights from technology attachés and FIT's Deputy Directors Trade For more details, visit: https://lnkd.in/efdYuT2t 📍 5 & 6 November | Skyhall, Brussels Airport #FIBS2024 #Convention

🌟 Last week, we hosted another #OPINNO event in collaboration with HOWEST University of Applied Sciences/VIVES University of Applied Sciences! 🌟 OPINNO brought together STEM students and life sciences professionals to explore diverse career paths within the #lifesciences industry. Through inspiring presentations and engaging roundtable discussions, students gained valuable insights into the opportunities that await them in our sector. We’re excited to continue supporting the next generation of biotech talent here in Flanders! A big thank you to our fantastic speakers and to everyone who supported the event: Silke Caestecker - Tristan Vanneste - Filip Van Houtte - Helena Vanluchene - Stefanie Devos - Annick Keirsebilck - Bart Quartier #STEMCareers 📢 Don't forget to register for OPINNO Antwerp (27/11): https://lnkd.in/eX7N8wDZ

Harpago is now a member of the flanders.bio network. Harpago develops formulations for poorly water-soluble therapeutics, to enhance solubility and bioavailability in discovery, preclinical and early clinical projects. “The majority of small-molecule therapeutics emerging from today's discovery pipelines are too poorly water-soluble to enable adequate bioavailability after oral intake. This solubility problem greatly hinders drug development, and ultimately prevents patients from accessing new treatments. At Harpago, we tackle this solubility problem.” #NewMember #therapeutics #solubility #bioavailability #formulations

BioSPX BV announces a new partnership with HAWK Biosystems, a leader in spatial biology technologies, to bring cutting-edge innovations to its customers. With the QF-Pro, HAWK sets a new spatial biology standard for quantitative analysis of protein functions in tissue and cells with a resolution <10nm. The QF-Pro is a revolutionary technology that enables scientists to spatially map protein-protein interactions and protein post-translation modifications.

4Tissue, a pioneering biotech company revolutionizing regenerative medicine with its cutting-edge, bioresorbable hydrogel tissue mimic, has completed a €2M seed funding round including equity investment and non-dilutive grants. Led by three prominent female investors from the life science and business sectors, this funding will enable 4Tissue to accelerate the clinical development of its innovative platform. This investment underscores the transformative potential of 4Tissue in women’s health.

🌟 NIEUW EVENT : EXPO AGRITECH MALAGA! 🌱🚀     Flanders Investment & Trade (FIT) zal van 26 tot 28 november aanwezig zijn met een onthaalstand op deze nieuwe beurs.     Binnen de EU zit Spanje bij de top voor wat betreft het aantal telers en agri-bedrijven en is het bovendien een belangrijke handelspartner voor Vlaamse exporteurs. De ideale gelegenheid dus om in een vroeg stadium de opportuniteiten te ontdekken voor jouw innovatief product of dienst in deze sector.    🎟️ FIT heeft 20 GRATIS VIP kaarten beschikbaar! Deze geven je de volle 3d toegang tot dit event, inclusief deelname aan alle workshops en conferenties. Bij interesse graag een mailtje naar madrid@fitagency.com 👈 Bezoek de beurs: 🔗 bit.ly/3U5H4Sy Wil je nu al meedingen naar de award voor de meest innovatieve oplossing kan je hiervoor nog je deelnameformulier indienen tot 15.10: 🔗bit.ly/3A1SyiQ Dirk Schamphelaere | Katlijn Mertens    #ExpoAgriTech #Innovation #AgriTech #Startups #Scaleups #FlandersinvestmentandTrade #Flanders

Biotalys announces the appointment of Kamal El Mernissi as Chief Business Development Officer (CBDO). Kamal El Mernissi, CBDO: “During my initial interactions, I was impressed by the team and sensed their excitement and motivation to develop protein-based biocontrols to positively impact the wider Ag community.” Kevin Helash, CEO: “I had the pleasure of working with Kamal as part of my team at Marrone Bio Innovations and am delighted to welcome him to the executive leadership at Biotalys.” Simon Moroney, Chairman:  “With more than 15 years of experience in agriculture and a broad variety of leadership positions in marketing and sales, he is an excellent addition to the leadership team.” https://lnkd.in/eCsSmA2T 

A study by a team led by Prof. Pierre Vanderhaeghen (VIB-KU Leuven) has been published in Neuron. It provides a surprisingly direct link between two genes present only in human DNA and a key gene called SYNGAP1, which is mutated in intellectual disability and autism spectrum disorders. Dr. Baptiste Libé-Philippot: “We discovered that when you turn off these genes in human neurons, synaptic development speeds up at remarkable levels. This mirrors the accelerated synapse development observed in certain forms of autism spectrum disorder.” Prof. Pierre Vanderhaeghen: “It is amazing to find out that the same genes that are involved in the evolution of the human brain also have the potential to modify the expression of specific brain diseases. It becomes conceivable that some human-specific gene products could become innovative drug targets.” https://lnkd.in/eb-VyjQ6 #HumanBrainEvolution #DevelopmentalDisorders #SYNGAP1 #IntellectualDisability #AutismSpectrumDisorders Columbia University Ecole normale supérieure Cell Press

Last week, #OPINNO at Hasselt University brought students face-to-face with #lifesciences experts to explore career paths and gain insights into industry roles. From bioinformatics to clinical development, R&D, and more, these professionals provided a detailed look into their daily roles and responsibilities, offering students a unique chance to ask questions about working in the life sciences industry. Thanks to: Annelies Vanheel - An Voets - Michaël Porcu - Nick Smisdom - Marten Achten - Bram Janssen - Thalysia Larosse - Charlotte Wuyts and Bianca Stals Next OPINNO: 22 October | Roeselare ➡ https://lnkd.in/eBYecQWa #STEMCareers - Faculteit Geneeskunde en Levenswetenschappen UHasselt

UZ Leuven and KU Leuven are setting up an innovative facility for the production of Advanced Therapy Medicinal Products (ATMP) on the Gasthuisberg campus, to produce tailor-made treatments for individual patients. Prof Paul Herijgers, CEO of UZ Leuven: ‘UZ Leuven has been a pioneer in the field of rare diseases for years and has extensive expertise in the diagnosis of genetic syndromes. A new production facility for ATMP will allow doctors and researchers to develop therapies tailored to the genetic disorder or to the patient's cancer.’ Bart Geers, investment manager at KU Leuven Research & Development: ‘With a new infrastructure, we will produce advanced or experimental cell-based therapies to industry standards at the hospital. New therapy options will be available to patients faster.’ https://lnkd.in/ekiK2x3V #MemberNews #ATMP #Gasthuisberg #facility #GeneticDisorders